Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients
Infertility
About this trial
This is an interventional treatment trial for Infertility
Eligibility Criteria
Inclusion Criteria:
- All patients have PCOS.
- All patients received CC 100 mg/day for 5 days starting from day 5 with successful ovulation as documented by folliculometry and midluteal serum progesterone with no pregnancy achieved.
- All patients have patent fallopian tubes by Hysterosalpingography.
- Their husbands have normal semen analysis according to the modified criteria of WHO.
- All patients have normal serum prolactin and thyroid profile.
- Any patient having vaginitis was treated before starting induction.
Exclusion Criteria:
- Other causes of infertility than anovulation.
- Diabetes or other endocrinological disorders.
- Age > 40 years.
- Smoking.
- Alcohol use.
- Presence of ovarian cyst >2cm on the second day of the cycle.
- Patients who have received gonadotrophins in the preceeding 6 months.
- Patients who have done unilateral or bilateral ovarian drilling.
- Allergy to PE, NO donors or NAC
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Phytoestrogen
Isosorbid mononitrate
N-Acetyl cysteine
Patients received oral PE 120 mg/ day in the form of dry coated tablets (Klimadynon, Bionorica, Germany) 2 tablets three times daily from day 1 to day 12 as adjuvant to CC in the follicular phase of the cycle.
Patients received in addition to CC 20 mg Isosorbid mononitrate (ISMN) tablet (EFFOX, Minapharm Co., Egypt under licence of Shwartz pharma,Germany) applied vaginally from day 1 to day 12 of the cycle.
Patients received supplementation to CC with NAC 1200 mg/day orally (N-acetyl cysteine, Sedico, Cairo, ARE) sachets 200 mg each, as two sachets thrice daily from day 1 to day 12 of the cycle.